Johnson & Johnson makes $15 billion bet on mental-health drugs
Johnson & Johnson said Monday it expects to accelerate sales growth beyond Wall Street expectations in the field of neuroscience with the $14.6 billion acquisition of Intra-Cellular Therapies Inc. It’s by far the largest of a trio of acquisitions by big pharmaceutical companies on Monday including deals from Eli Lilly & Co.
Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal
Johnson & Johnson has entered an agreement to acquire all outstanding shares of Intra-Cellular Therapies, in a multibillion-dollar bet on mental health therapies. Johnson & Johnson will pay $132 per share in cash for a total equity value of $14.
Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression
J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal
Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the market for brain disease treatments.
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and
Cautious Optimism: Evaluating Johnson & Johnson’s Hold Rating Amid ITCI Acquisition Uncertainties
Wells Fargo analyst Larry Biegelsen has maintained their neutral stance on JNJ stock, giving a Hold rating yesterday.Stay Ahead of the ...
Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal
Johnson & Johnson agreed to acquire Intra-Cellular Therapies for $132 a share in cash for a total equity value of about $14.6 billion. The health-care company Monday said the deal adds to its ...
Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...
Johnson & Johnson stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
MassDevice5d
Johnson & Johnson MedTech halts Varipulse PFA cases due to stroke reports
Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...